NTLA:NSD-Intellia Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 21

Change

0.00 (0.00)%

Market Cap

USD 2.13B

Volume

1.12M

Analyst Target

USD 30.15
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 35.29B
ARGX argenx NV ADR

N/A

USD 32.06B
MRNA Moderna Inc

N/A

USD 25.25B
BGNE BeiGene Ltd

N/A

USD 24.38B
RPRX Royalty Pharma Plc

N/A

USD 16.72B
UTHR United Therapeutics Corporatio..

N/A

USD 15.71B
SMMT Summit Therapeutics PLC

N/A

USD 15.35B
PCVX Vaxcyte Inc

N/A

USD 14.00B

ETFs Containing NTLA

XDNA 8.89 % 0.00 %

N/A

N/A
ARKG 5.09 % 0.75 %

N/A

N/A
ARKG:LSE ARK Genomic Revolution UC.. 5.03 % 0.00 %

N/A

USD 3.09M
ARCG:LSE ARK Genomic Revolution UC.. 4.89 % 0.00 %

N/A

USD 3.03M
MSGR 4.67 % 0.00 %

N/A

N/A
ARKK ARK Innovation ETF 3.32 % 0.75 %

N/A

USD 5.85B
XSU:CA iShares US Small Cap (CAD.. 0.00 % 0.36 %

N/A

CAD 0.73B
IBBJ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -31.12% 25% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -31.12% 25% F 23% F
Trailing 12 Months  
Capital Gain -33.59% 22% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.59% 22% F 22% F
Trailing 5 Years  
Capital Gain 57.30% 58% F 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 57.30% 58% F 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 92.39% N/A N/A 94% A
Dividend Return 92.39% N/A N/A 94% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 216.78% N/A N/A 8% B-
Risk Adjusted Return 42.62% N/A N/A 72% C
Market Capitalization 2.13B 89% A- 80% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector